The weekly litigation news digest is live. Subscribe now

IP Verse

Transgenic Mouse Which Produces Hybrid Antibodies Containing Human Variable Regions And Mouse Constant Regions - EP3626819

The patent EP3626819 was granted to Regeneron Pharmaceuticals on Mar 31, 2021. The application was filed on Feb 15, 2002 under application number EP19203913A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3626819

REGENERON PHARMACEUTICALS
Application Number
EP19203913A
Filing Date
Feb 15, 2002
Status
Granted And Under Opposition
Feb 26, 2021
Publication Date
Mar 31, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
KYMABDec 22, 2021CMS CAMERON MCKENNA NABARRO OLSWANGWITHDRAWN

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20010784859
DESCRIPTIONUS5350689
DESCRIPTIONUS5436149
DESCRIPTIONUS5508189
DESCRIPTIONUS5770429
DESCRIPTIONUS5789215
SEARCHUS6114598
SEARCHWO9100906
SEARCHWO9945962

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents